An Investigation of Levetiracetam in Alzheimer's Disease
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The study proposed aims to evaluate the effect of Levetiracetam in patients with Alzheimer's
disease (AD) in a Phase 2 Clinical Trial.
Levetiracetam is an established anti-epileptic medication that has been approved by NICE (UK)
as a first line treatment for focal epilepsy. Levetiracetam is now generic and acts, as all
anti-epileptic medications do, by stabilising neuronal networks. However, Levetiracetam
appears unique amongst the anti-epileptic medications in being able to stabilise aberrant
neuronal networks in Alzheimer's disease. In both animal models of AD and in patients with
mild cognitive impairment, Levetiracetam can offer benefit to cognition.
The investigators therefore aim to test whether Levetiracetam, through stabilisation of
neuronal networks, may offer benefit to cognition in patients with AD.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oxford
Collaborators:
Northumberland, Tyne and Wear NHS Foundation Trust Oxford Health NHS Foundation Trust Oxford University Hospitals NHS Trust UCB Pharma